Literature DB >> 20432232

The pericyte and stromal cell marker CD248 (endosialin) is required for efficient lymph node expansion.

Siân Lax1, Debbie L Hardie, Amy Wilson, Mike R Douglas, Graham Anderson, David Huso, Clare M Isacke, Christopher D Buckley.   

Abstract

CD248 is a cell surface receptor that specifically identifies fibroblasts and pericytes during development and in association with cancer and inflammation. However, its function is poorly defined and its role in lymphoid organs not studied. Here, we used (4-hydroxy-3-nitrophenyl)acetyl chicken gamma-globulin immunisation and mice lacking CD248 to study whether CD248 modulates popliteal LN (pLN) expansion and subsequent immune responses. We have found that CD248 is required for complete pLN expansion but not for co-ordination of B and T cell compartmentalisation or antibody production following (4-hydroxy-3-nitrophenyl)acetyl chicken gamma-globulin immunisation. In vitro, we show that CD248 expression in human MG63 stromal cells and mouse embryonic fibroblasts leads to a pro-proliferative and pro-migratory phenotype. This correlates with a proliferating CD248(+) population observed in vivo during pLN expansion. Taken together, these data highlight a role for CD248 in secondary lymphoid organ remodelling during adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20432232      PMCID: PMC3095484          DOI: 10.1002/eji.200939877

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Stromal cell heterogeneity in lymphoid organs.

Authors:  Manuela Buettner; Reinhard Pabst; Ulrike Bode
Journal:  Trends Immunol       Date:  2009-12-05       Impact factor: 16.687

2.  A novel role for PECAM-1 in megakaryocytokinesis and recovery of platelet counts in thrombocytopenic mice.

Authors:  Tarvinder S Dhanjal; Caroline Pendaries; Ewan A Ross; Mark K Larson; Majd B Protty; Chris D Buckley; Steve P Watson
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

3.  Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration.

Authors:  Brian Tomkowicz; Katherine Rybinski; Brian Foley; Wolfgang Ebel; Brad Kline; Eric Routhier; Philip Sass; Nicholas C Nicolaides; Luigi Grasso; Yuhong Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-06       Impact factor: 11.205

4.  Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers.

Authors:  Rebecca G Bagley; William Weber; Cecile Rouleau; Min Yao; Nakayuki Honma; Shiro Kataoka; Isao Ishida; Bruce L Roberts; Beverly A Teicher
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

5.  Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes.

Authors:  Nahed M Hawsawi; Hazem Ghebeh; Siti-Faujiah Hendrayani; Asma Tulbah; Maha Al-Eid; Taher Al-Tweigeri; Dahish Ajarim; Ayodele Alaiya; Said Dermime; Abdelilah Aboussekhra
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

6.  T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching.

Authors:  K M Toellner; S A Luther; D M Sze; R K Choy; D R Taylor; I C MacLennan; H Acha-Orbea
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

7.  CD248/Endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair.

Authors:  Siân Lax; Tie Zheng Hou; Eric Jenkinson; Mike Salmon; John R MacFadyen; Clare M Isacke; Graham Anderson; Adam F Cunningham; Christopher D Buckley
Journal:  FEBS Lett       Date:  2007-07-03       Impact factor: 4.124

8.  Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma.

Authors:  Nicole Simonavicius; David Robertson; Dorine A Bax; Chris Jones; Ivo J Huijbers; Clare M Isacke
Journal:  Mod Pathol       Date:  2008-01-11       Impact factor: 7.842

9.  Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2.

Authors:  A Ohradanova; K Gradin; M Barathova; M Zatovicova; T Holotnakova; J Kopacek; S Parkkila; L Poellinger; S Pastorekova; J Pastorek
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

10.  The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways.

Authors:  Edward M Conway; Marlies Van de Wouwer; Saskia Pollefeyt; Kerstin Jurk; Hugo Van Aken; Astrid De Vriese; Jeffrey I Weitz; Hartmut Weiler; Peter W Hellings; Paul Schaeffer; Jean-Marc Herbert; Désiré Collen; Gregor Theilmeier
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

View more
  19 in total

1.  Characterization and angiogenic potential of human neonatal and infant thymus mesenchymal stromal cells.

Authors:  Shuyun Wang; Lakshmi Mundada; Sean Johnson; Joshua Wong; Russell Witt; Richard G Ohye; Ming-Sing Si
Journal:  Stem Cells Transl Med       Date:  2015-02-23       Impact factor: 6.940

2.  The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice.

Authors:  Amy J Naylor; Eman Azzam; Stuart Smith; Adam Croft; Callum Poyser; Jeremy S Duffield; David L Huso; Steffen Gay; Caroline Ospelt; Mark S Cooper; Clare Isacke; Simon R Goodyear; Michael J Rogers; Christopher D Buckley
Journal:  Arthritis Rheum       Date:  2012-10

3.  The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferation.

Authors:  Debbie L Hardie; Mathew J Baldwin; Amy Naylor; Oliver J Haworth; Tie Zheng Hou; Sian Lax; S John Curnow; Nick Willcox; John MacFadyen; Clare M Isacke; Christopher D Buckley
Journal:  Immunology       Date:  2011-04-06       Impact factor: 7.397

4.  CD248 expression on mesenchymal stromal cells is required for post-natal and infection-dependent thymus remodelling and regeneration.

Authors:  Siân Lax; Ewan A Ross; Andrea White; Jennifer L Marshall; William E Jenkinson; Clare M Isacke; David L Huso; Adam F Cunningham; Graham Anderson; Christopher D Buckley
Journal:  FEBS Open Bio       Date:  2012-07-20       Impact factor: 2.693

5.  CD248 facilitates tumor growth via its cytoplasmic domain.

Authors:  Margarida Maia; Astrid DeVriese; Tom Janssens; Michaël Moons; Rik J Lories; Jan Tavernier; Edward M Conway
Journal:  BMC Cancer       Date:  2011-05-08       Impact factor: 4.430

Review 6.  Characteristics of human Ewing/PNET sarcoma models.

Authors:  Beverly A Teicher; Rebecca G Bagley; Cecile Rouleau; Ariel Kruger; Yi Ren; Leslie Kurtzberg
Journal:  Ann Saudi Med       Date:  2011 Mar-Apr       Impact factor: 1.526

7.  Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells.

Authors:  Michael Rosu-Myles; Yi-Min She; Joel Fair; Gauri Muradia; Jelica Mehic; Pablo Menendez; Shiv S Prasad; Terry D Cyr
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

8.  Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins.

Authors:  Daniel J O'Shannessy; Elizabeth B Somers; Lakshmi K Chandrasekaran; Nicholas C Nicolaides; Jennifer Bordeaux; Mark D Gustavson
Journal:  Oncotarget       Date:  2014-06-30

9.  Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals Niche-Associated Heterogeneity.

Authors:  Lauren B Rodda; Erick Lu; Mariko L Bennett; Caroline L Sokol; Xiaoming Wang; Sanjiv A Luther; Ben A Barres; Andrew D Luster; Chun Jimmie Ye; Jason G Cyster
Journal:  Immunity       Date:  2018-05-08       Impact factor: 31.745

10.  Hypertrophy of infected Peyer's patches arises from global, interferon-receptor, and CD69-independent shutdown of lymphocyte egress.

Authors:  O Schulz; M Ugur; M Friedrichsen; K Radulovic; J-H Niess; S Jalkanen; A Krueger; O Pabst
Journal:  Mucosal Immunol       Date:  2013-12-18       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.